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Introduction: Invasive mucormycosis (zygomycosis) is the third most frequent fungal infection in patients with
hematologic malignancies. It often results in a fatal outcome mainly due to the difficulty of early diagnosis and its
resistance to antimycotics.
Case presentation: A 52-year-old Caucasian man was diagnosed with acute myeloblastic leukemia. Following the
induction chemotherapy he developed febrile neutropenia. Meropenem (3×1000mg/day) was introduced empiric-
ally. A chest computed tomography showed soft-tissue consolidation change in his right upper lobe. A bronchos-
copy was performed and the histology indicated invasive pulmonary aspergillosis based on fungal hypha detection.
Also, high risk patients are routinely screened for invasive fungal infections using commercially available serological
enzyme-linked immunosorbent assay tests: galactomannan and mannan (Bio-Rad, France), as well as anti-Aspergillus
immunoglobulin G and/or immunoglobulin M and anti-Candida immunoglobulin G and/or immunoglobulin M
antibodies (Virion-Serion, Germany). Galactomannan showed low positivity and voriconazole therapy (2×400mg/first
day; 2×300mg/following days) was implemented. The patient became afebrile and a partial remission of disease
was established. After 2 months, the patient developed a fever and a chest multi-slice computed tomography
showed soft-tissue mass compressing his upper right bronchus. Voriconazole (2×400mg/first day; 2×300mg/follow-
ing days) was reintroduced and bronchoscopy was repeated. Histologic examination of the new specimen was
done, as well as a revision of the earlier samples in the reference laboratory and the diagnosis was switched to inva-
sive pulmonary mucormycosis. The treatment was changed to amphotericin B colloidal dispersion (1×400mg/day).
The complete remission of acute myeloblastic leukemia was verified after 2 months. During his immunerestitution,
a high positivity of the anti-Aspergillus immunoglobulin M antibodies was found in a single serum sample and
pulmonary radiography was unchanged. A lobectomy of his right upper pulmonary lobe was done and the
mycology culture of the lung tissue sample revealed Rhizopus oryzae. He remained in complete remission for
more than 1 year.
Conclusions: Invasive mucormycosis was successfully treated with amphotericin B, surgery and secondary
itraconazole prophylaxis. As a rare disease invasive mucormycosis is not well understood by the medical
community and therefore an improvement of education about prevention, diagnosis and treatment of invasive
mucormycosis is necessary.
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Invasive mucormycosis (IMM;zygomycosis) is the third
most frequent invasive fungal infection (IFI) in patients
with hematologic malignancies, often resulting in a
fatal outcome due to the difficulty of early diagnosis
and its resistance to antimycotics [1]. IMM is life-
threatening and an emerging infection caused by the
ubiquitous filamentous fungi from the Glomeromycota
phylum, Zygomycota class and Mucorales order, which
include, among others, the Mucoraceae family with
genera: Rhizopus, Mucor, Rhizomucor, Lichtheimia and
Apophysomyces.
Case presentation
A 52-year-old Caucasian man was diagnosed with acute
myeloblastic leukemia (AML) with an intermediary risk
group according to the European Leukemia Net [2] in
our hospital. Induction chemotherapy was introduced
with the “3+7” scheme: Daunoblastina® (daunorubicin)
45mg/kg/body weight (bw) during 3 days and cytosine
arabinoside 200mg/kg/bw during 7 days. Post-induction
bone marrow aplasia developed on day 4 of the therapy,
with a fever (38°C) appearing a day before. Chest X-ray
results were normal and meropenem (3×1000mg/day)
was empirically introduced. Due to persistent fever, on
day 8 of the chemotherapy, caspofungin was empirically
introduced intravenously (70mg/first day; 50mg/following
days). Also, high risk patients are routinely screened for IFIs
using commercially available serological enzyme-linked
immunosorbentassay tests: galactomannan (GM) and man-
nan (Bio-Rad, France), as well as anti-Aspergillus immuno-
globulin (Ig)G and/or IgM and anti-Candida IgG and/or
IgM antibodies (Ab; Virion-Serion, Germany). Only one
serum sample showed low positivity for GM (index 0.55).
On day 14 of therapy, the control chest X-ray showed
homogenous opacity of his upper right lobe implying a
probable focal pneumonia. Chest computed tomography
(CT) verified atelectasis of the lobe with distal pneumonitis
(Figure 1A). Bronchoscopy was done on day 31 and
histology revealed fungal hyphae suggesting invasive pul-
monary aspergillosis (IPA). Voriconazole was introduced
(2×400mg/first day; 2×300mg/following days). A control
bone marrow biopsy showed partial hematological remis-
sion of the AML. On day 44 of hospitalization, the patient
was discharged with a normal blood count. On the second
hospitalization (1 month later) the patient had no subjective
complaints and his blood count was normal. A chest CT
showed deformation and constriction of all bronchial
segments in his pulmonary upper right lobe. There were
interlobular septal and nodular (up to 1cm) opacities.
Suspected clot masses were seen in the lumen of the
superior vena cava, inferior vena cava, azygos vein and
splenic vein (Figure 1B). The patient received re-induction
chemotherapy, “3+7” in the same dose, and voriconazoletherapy (2×400mg/first day; 2×300mg/following days) was
continued as a secondary prophylaxis of IPA. On day 5 of
chemotherapy he developed high fever (38.5°C to 40.5°C)
and a bronchoscopy was repeated. Direct microscopic
examination was done with a bronchoalveolar lavage (BAL)
sample, and it was negative.
Histologic examination of the new specimen was done,
as well as a revision of the earlier samples in the refer-
ence laboratory and the diagnosis was switched to pul-
monary IMM (Figure 1C). Voriconazole therapy had
been stopped and changed to amphotericin B (AmB)
colloidal dispersion (ABCD) treatment (1×400mg/day).
Concurrently, GM showed low positivity in one serum
sample while other biomarkers for IFI were negative. A
chest CT, done 2 months after second hospitalization,
confirmed a persistence of consolidation of the larger
part of his upper right pulmonary lobe. The follow-up
bone marrow biopsy showed a complete morphological
remission of AML. The patient was discharged and sec-
ondary prophylaxis with itraconazole (the only available
antimold drug for out-patients in Serbia) (2×200mg/day)
was started. On the third hospitalization (after 2
months), the patient complained of cough, blood-
streaked sputum, and low fevers. He was in complete
remission of AML. A multi-slice chest CT showed signs
of minor regression of inflammatory consolidation and
the thrombotic masses were not seen (Figure 2). The pa-
tient received high-dose consolidation chemotherapy
(cytosine arabinoside 3g/m2, from D1 to D3). Daily 4
mg/kg/bw of ABCD was reintroduced. The patient
developed iatrogenic bone marrow aplasia on day 11
of hospitalization and became febrile. On day 13,
hemoptysis, hypotension and septic shock were developed.
Manual heart resuscitation and intensive infusion therapy
with dopamine hydrochloride infusions were applied
(250mg/500mL sodium chloride). A follow-up chest CT
was done and showed minor regression of his pulmonary
lesions. At the same time IFI early laboratory biomarkers
showed a high positive level of anti-Aspergillus IgM
(420U/mL). A lobectomy of his upper right lobe was
done on day 60 during the third hospitalization.
Mycology culture of his lung tissue sample revealed
Rhizopus oryzae. A secondary prophylaxis with itraco-
nazole (2×200mg/day) was done during the next 3
months and the patient remained in remission for
more than 1 year.
Discussion
IMM has emerged as the third most common IFI in pa-
tients with hematological malignity and the second most
frequent lethal invasive mold infection in those patients
[1]. The epidemiological data on IMM are still sparse,
thus making determination of the burden of the disease
challenging [3]. The incidence of IMM is hard to
Figure 1 (See legend on next page.)
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Figure 1 Findings of pulmonary mucormycosis detected by computed tomography (A, B) and multi-slice computed tomography (C).
A) First hospitalization, soft-tissue alveolar-consolidation changes of the anterior and posterior segment of the upper lobe (arrow). B) Second
hospitalization, peribronchial circular thickening, with deformation and constriction of all bronchial segments, with peribronchial propagation in
the form of irregular, interlobular septal and nodular (up to 1cm) opacities (arrow). Suspected clot masses were viewed in the lumen of the
superior vena cava, inferior vena cava, azygos vein and splenic vein. C) Third hospitalization, the signs of minor regression of the soft-tissue
inflammatory consolidation of the upper right lobe (arrow).
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this problem. The incidence of IMM in United States of
America is 1.7 newly diagnosed infections/million [4].
The risk factors of IMM are numerous and very similar
to those which predict other mold IFI. The following
predisposing factors are of especial significance: long-
term neutropenia (>3 weeks), absolute neutrophil count
(<200/mm3), monocytopenia (<100/mm3), graft-versus-
host-disease, allogeneic bone marrow transplant, long-
term corticosteroid treatment (>1mg/kg/bw), total body
iron burden, prolonged hyperglycemia, relapsing and re-
fractory leukemia, previous Aspergillus infection, as well
as earlier antifungal voriconazole or echinocandin ther-
apy [5]. The key factor for the fast progression of IMM
is the angioinvasion by the fungal hyphae, which may
cause tissue necrosis and thromboses of the blood ves-
sels, as was shown in our patient [6]. There are six clin-
ical forms of IMM: rhinocerebral, pulmonary, cutaneous,
gastrointestinal, disseminated and uncommon presenta-
tions [3]. In patients with malignant hemopathies on
high-dose combined chemotherapy, the pulmonary formFigure 2 Cytology findings of pulmonary tissue obtained by
biopsy led to diagnosis of mucormycosis; after retesting in a
mycology reference laboratory the diagnosis was revised to
invasive pulmonary mucormycosis based on wide nonseptic
hyphae, suggesting filamentous fungi of the order Mucorales.
Hematoxylin and eosin staining × 400; marked with arrows.of IMM is seen often and can be followed by dissemin-
ation and a lethal outcome [7]. Our patient had key pre-
disposing factors for IMM, such as post-chemotherapy
iatrogenic neutropenia and empirical treatment with cas-
pofungin. Even though the diagnostics of IMM is difficult,
lacking typical symptoms, signs of disease and specific early
laboratory biomarkers, in our case the diagnosis was estab-
lished by conventional methods and contributed to the
proper therapy and a favorable outcome [8].
The definite diagnosis of IMM is hard to establish and
often requires invasive procedures such as tissue biopsy
and histological examination or in vitro culture. Conse-
quently, a diagnosis of IMM is often made postmortem
[6]. Timely discrimination between IMM and invasive
aspergillosis (IA) is critical for adequate treatment. In re-
lation to CT presentation of IMM and IA, the most sug-
gestive indicator of IMM is the evidence of multiple
pulmonary nodules (>10) as well as a pleural effusion.
Our patient was initially diagnosed with IPA based on
local epidemiology data, low positive GM test, consoli-
dation changes in the lung and the histological proof of
fungal hyphae. However, the progression of pulmonary
infiltration, development of thrombotic masses in the
pulmonary artery, multiple nodule changes in the lung
and pleural effusion despite voriconazole treatment led
to a revision of the IPA diagnosis, and a new diagnosis,
IMM, was proved, which required a well-trained mycolo-
gist. The possibility of Aspergillus co-infection cannot be
excluded, but the chest CT showed that therapy with vori-
conazole resulted in a progression of infiltration, while the
histology and mycology investigations on the lung and BAL
samples were negative for Aspergillus. In the present con-
text, we speculate that the high levels of anti-Aspergillus
IgM Ab may be attributed to cross-reactivity with fungal
antigens from the Mucoraceae family. It is well known that
IgM Ab have potential cross-reactivity among different
virus families, several parasites and Spirochaeta proteins
which could affect the interpretation of some laboratory
tests. In spite of that, there is little data about cross-
reactivity between different fungal families and further in-
vestigation should improve on this.
The treatment of IMM is difficult and fluconazole,
voriconazole, flucytosine and echinocandin have negli-
gible effects on IMM. The drug of choice is AmB, as
well as lobectomy according to the recommendation of
the Expert Medical Board [9], but also posaconazole and
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[10]. Combined antifungal therapy is also recommended,
usually including AmB and echinocandin or posaconazole
[11]. However, surgical treatment is often crucial for IMM
[12]. Also, immunotherapy is recommended [13] as well as
iron chelating and hyperbaric oxygenation [14,15].
Conclusions
In our patient, the treatment with ABCD (for 5 weeks),
lobectomy, recovery from neutropenia and itraconazole
prophylaxis (for 17 weeks) led to recovery from IMM. Also,
we take into consideration potential cross-reactivity of Ab
between different fungus families. So, a negative serology
finding during neutropenia converted to a high positive
level of anti-Aspergillus IgM Ab during his immune restitu-
tion. This fact can confuse medical doctors in making the
right decision especially in the absence of specific early
laboratory biomarkers for IMM. In conclusion, the “gold
standard” for IMM diagnosis is a conventional diagnosis
based on lung histology or BAL cytology. IMM, as a rare
disease, is not well understood by the medical community.
Therefore an improvement of education about prevention,
diagnosis and treatment is essential and we believe that the
description of this case may contribute to that [8].
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